Y-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025

Core Insights - Y-mAbs Therapeutics, Inc. is set to report its second quarter 2025 results on August 8, 2025, before market opening [1] - The company will not host an earnings conference call due to a previously announced transaction with SERB Pharmaceuticals [2] Company Overview - Y-mAbs is a commercial-stage biopharmaceutical company focused on developing and commercializing antibody-based therapeutics for cancer treatment [3] - The company's product pipeline includes DANYELZA (naxitamab-gqgk), the first FDA-approved treatment for relapsed or refractory high-risk neuroblastoma [3] - Y-mAbs utilizes innovative technologies such as the Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform (PRIT) and bispecific antibodies from the Y-BiClone platform [3]